Extending Telehealth for Medicare Recipients

The following is an email from the US Pain Foundation dated yesterday, March 21:

Since access and coverage of telehealth has been a wonderful and safe convenience for people with chronic pain during the pandemic, we have been closely following government policy around telehealth coverage and want to update you on recent developments.

Last week, President Biden signed into law HR 2471, the Consolidated Appropriations Act of 2022 which finalized the fiscal year 2022 federal budget and included a number of provisions to extend Medicare telehealth coverage implemented as part of the government’s response to COVID-19. The COVID-19 Public Health Emergency (PHE) has not yet officially ended but is expected to end sometime in the next few months. HR 2471 will extend Medicare telehealth coverage for 151 days or approximately five months after the PHE ends. These extensions include the following:

  • Patients’ Location – Medicare beneficiaries can continue to receive coverage for telehealth services from wherever they are located within the U.S., including their homes. Before the PHE, telehealth coverage was restricted to beneficiaries being located in hospitals and certain provider locations in order to receive coverage for telehealth.
  • Eligible Practitioners – Medicare beneficiaries can continue to receive coverage for telehealth services from physical therapists and occupational therapists.
  • Mental Health Coverage – Medicare beneficiaries can continue to receive coverage for telehealth services from mental health providers without the requirement of an in-person visit within six months of the first telehealth service with that provider nor the requirement of an in-person visit every 12 months.
  • Audio-only Telehealth – Medicare beneficiaries can continue to receive coverage for telehealth services using audio-only technology.

This is great news for Medicare beneficiaries! However, although Medicare coverage policies tend to be a bellwether for changes in private payer and Medicaid coverage, please keep in mind that private payer and Medicaid coverage for telehealth services varies by state.

Forty-three states and the District of Columbia (DC) have laws that govern private payer reimbursement of telehealth but what specific services and providers are covered varies greatly. And, while all 50 states and DC now reimburse for some types of telehealth services in Medicaid, many of the reimbursement policies have restrictions and limitations. It is important to check with your state Medicaid program or private insurer to find out what telehealth services are covered.

You can learn more about the efforts that the US Pain Foundation takes around advocacy – including ways to get involved – here.

Abivax Reports Promising ABX464 Phase 2a One-Year Maintenance Results in Rheumatoid Arthritis

Below is a press release dated today (3/10/22) from Abivax:

The Quick Basics

Out of the 40 patients who enrolled into the ABX464 maintenance study, 23 patients have now reached the first year of treatment and all achieved at least an ACR201, with 19 and 12 patients achieving ACR50 and ACR70 respectively.

Long-term safety profile (50mg ABX464 once daily + MTX) favorable and consistent with previous observations.

The induction and maintenance results support further clinical development of ABX464 in RA and potentially other rheumatology indications.

The clinical induction and maintenance data in ulcerative colitis and rheumatoid arthritis underpin the potential of ABX464 to address a broad range of chronic inflammatory diseases.

In G7 countries, the market for ulcerative colitis, Crohn’s disease and rheumatoid arthritis is expected to grow to approximately USD 50B in 2026.

The Full Press Release

Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today reports promising results from its phase 2a maintenance trial in rheumatoid arthritis (RA) after one year of continued daily treatment with 50mg ABX464.

Continue reading “Abivax Reports Promising ABX464 Phase 2a One-Year Maintenance Results in Rheumatoid Arthritis” →

Autoimmune Community Institute to Host Inaugural Autoimmune Health Equity Summit [postponed]

Update:

With deep sadness, the Autoimmune Community Institute announces today that we must postpone the Inaugural Autoimmune Health Equity Summit originally planned for Saturday, March 12 due to technical issues. 

While compiling our pre-recorded interviews to create the final product, we noticed that the video from some of our amazing speakers did not record. This error is not one that could have been foreseen or prevented, as this is the first time an error like this has occurred. As a result, we felt it necessary to postpone the event to rectify these issues and ensure our speakers can be seen and heard properly.

Dr. April Moreno, Founder at Autoimmune Community Institute has provided the following statement:

“Unfortunately, we experienced technical difficulties with the video service platform and will need time to correct some of the recordings for the event.”

Despite these unfortunate setbacks, registration will continue to be open for the postponed event, which will now occur on March 19, 2022, at 12pm Pacific Time (3pm Eastern Time. We continue to look forward to hosting the event and apologize again for any inconvenience or disappointment. 

_

The following is a press release dated March 7 from the Autoimmune Community Institute.

The Autoimmune Community Institute is dedicated to autoimmune health equity through community-based research and support services. The all-volunteer team strives to fulfill that mission by creating spaces for diverse autoimmune voices and experiences in community-centered research design, community support, and health equity advocacy every single day.

Today, ACI is taking a momentous step to further its mission and fulfill its goals by announcing the Inaugural Autoimmune Health Equity Summit. The ACI Health Equity Summit is our signature event to highlight the importance of diversity and representation in autoimmune communities.

This free event will discuss the importance of diversity and representation in research, policy, advocacy, and community support services; as well as the difference between equality and health equity and why we must work toward equity in all policies. Participants will also be introduced to some of our excellent partners in autoimmune health serving diverse communities.

The summit is designed for autoimmune patients, clinicians, researchers, and anyone who works with or has an interest in autoimmune topics. It will be held on March 12, 2022, at 12 pm Pacific Time (3 pm Eastern Time). Registration for the event is now open here! 

Please share this event widely within your networks. The staff at ACI is extremely excited to be hosting this event, and cannot wait to see you there!

autoimmune community institute logo